STOCK TITAN

InspireMD: Osiris buys 307,693 shares with warrants

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

InspireMD, Inc. director Paul Stuka reported that Osiris Investment Partners, L.P. purchased 307,693 common shares and 230,769 accompanying Series L common stock warrants in the company's underwritten public offering on November 13, 2026. The stated combined public offering price was $0.65 per share of common stock and accompanying warrants.

After the reported purchases, Osiris was reported to hold 731,397 common shares and 230,769 warrants. Stuka is managing member of Osiris's general partner and disclaims beneficial ownership except to the extent of his pecuniary interest. The warrants are immediately exercisable at $0.65 per share and expire November 16, 2027. No Rule 10b5-1 plan is reported.

Insider Stuka Paul
Role Director
Bought 538,462 shs ($200K)
Type Security Shares Price Value
Purchase Series L Common Stock Warrant F4, F2 230,769 $0.00 $0.00
Purchase Common Stock F1, F2 307,693 $0.65 $200K
Holding Common Stock F3 -- -- --
Holdings After Transaction: Series L Common Stock Warrant — 230,769 warrants (Indirect, See Footnote); Common Stock — 731,397 shares (Indirect, See Footnote); Common Stock — 667,871 shares (Direct)
Footnotes (4)
  1. F1. Represents shares of common stock purchased by the Reporting Person through Osiris Investment Partners, L.P. ("Osiris") in the Issuer's underwritten public offering at a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants.
  2. F2. These securities are held by Osiris. The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
  3. F3. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
  4. F4. The Series L common stock warrants are immediately exercisable at an exercise price of $0.65 per share and expire on November 16, 2027.
Common shares purchased 307,693 shares Purchased through Osiris in the underwritten public offering on November 13, 2026
Series L warrants 230,769 warrants Accompanying warrants reported in the November 13, 2026 offering transaction
Combined public offering price $0.65 per share of common stock and accompanying warrants Price stated for the offering securities
Common shares held indirectly after transaction 731,397 shares Reported as held through Osiris following the transaction
Warrants held after transaction 230,769 warrants Reported following the transaction
Warrant exercise price $0.65 per share Series L common stock warrants
Warrant expiration November 16, 2027 Series L common stock warrants
Directly held common shares 667,871 shares Listed in a separate holding entry; the footnote states no transaction was effected with respect to these securities
underwritten public offering financial
"in the Issuer's underwritten public offering"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
Series L common stock warrants technical
"The Series L common stock warrants are immediately exercisable"
pecuniary interest financial
"except to the extent of his pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NSPR shares and warrants did Osiris acquire?

Osiris Investment Partners, L.P. purchased 307,693 InspireMD common shares and 230,769 accompanying Series L common stock warrants on November 13, 2026. The stated combined public offering price was $0.65 per share of common stock and accompanying warrants.

What are the exercise terms for Osiris's NSPR warrants?

The 230,769 Series L warrants are immediately exercisable at $0.65 per share and expire November 16, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stuka Paul

(Last)(First)(Middle)
C/O INSPIREMD, INC.
6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)
MIAMI FLORIDA 33126

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/13/2026P307,693(1)A$0.65731,397(2)ISee Footnote
Common Stock667,871(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series L Common Stock Warrant(4)$0.6511/13/2026P230,76911/16/202611/16/2027Common Stock230,769$0.00230,769(2)ISee Footnote
Explanation of Responses:
1. Represents shares of common stock purchased by the Reporting Person through Osiris Investment Partners, L.P. ("Osiris") in the Issuer's underwritten public offering at a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants.
2. These securities are held by Osiris. The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
3. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
4. The Series L common stock warrants are immediately exercisable at an exercise price of $0.65 per share and expire on November 16, 2027.
/s/ Michael Lawless, Attorney-in-Fact for Paul Stuka11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading